Original Article

Genetic Characterization of the H Gene of MeV Strains (H1, B3, and D4) Recently Circulated in Iran for Improving the Molecular Measles Surveillance in the National Measles Lab

Abstract

Background: Despite decreasing the global burden of measles disease after the introduction of vaccination, measles remains one of the most devastating childhood diseases. Since genotype B3 is reported as a predominant Measles Virus (MeV) genotype recently, the current study aimed to better understand MeV genetic variation by analyzing the complete sequence of Hemagglutinin (H) gene associated with outbreaks of circulated genotypes in Iran.

Methods: Nine positive measles specimens were selected from three circulated different genotypes H1, B3, and D4. Two different regions of MeV RNA were detected by RT-PCR assay. Sequence data and phylogenetic trees were analyzed and constructed by MEGA X software program. Moreover, missense and silent mutations in critical positions of the MeV-H protein were investigated.

Results: The result of phylogenetic analysis from the C-terminus of the Nucleoprotein gene (NP-450) and the complete H gene revealed that the mean sequence diversity was 0.06%-0.08% and 0.04%, respectively. Genotype H1 had the highest mutation in this study; however, the substitutions in genotype B3 fundamentally occurred in critical epitopes. Moreover, genotype D4 was more stable than genotypes B3 and H1.

Conclusion: Mutations were investigated in the whole sequence of H protein. Moreover, the mutations that occur in the critical sites of the protein have an important effect on the pathogenicity of the virus. In this way, we were able to illustrate why genotype B3 is more transmissible than other measles genotypes and is the most important circulating genotype around the world.

1. William J Moss, Peter Strebel (2011). Biological feasibility of measles eradication. J Infect Dis, 1(Suppl 1):S47-53.
2. Tahara M, Ito Y, Brindley MA, et al (2013). Functional and structural characterization of neutralizing epitopes of MeV H protein. J Virol, 87(1):666-75.
3. Tahara M, Bürckert JP, Kanou K, et al (2016). MeV H protein epitopes: The basis of antigenic stability. Viruses, 8(8):216.
4. Massé N, Ainouze M, Néel B, et al (2004). MeV (MV) H: evidence that attachment sites for MV receptors SLAM and CD46 overlap on the globular head. J Virol, 78(17):9051-9063.
5. Hashiguchi T, Kajikawa M, Maita N, et al (2007). Crystal structure of MeV H provides insight into effective vaccines. Proc Natl Acad Sci U S A, 104(49):19535-19540.
6. Beaty SM, Lee B (2016). Constraints on the genetic and antigenic variability of MeV. Viruses, 8(4):109.
7. Progress towards regional measles elimination - worldwide, 2000-2016 (2017). Center for Disease Control and Prevention. https://www.cdc.gov
8. Salimi V, Abbasi S, Zahraei SM, et al (2014). Implementation of a National Measles Elimination Program in Iran: Phylogenetic Analysis of MeV Strains Isolated during 2010-2012 Outbreaks. PLoS One, 9(4):e94846.
9. Teleb N, Lebo E, Ahmed H, et al (2014). Progress toward measles elimination: EMR, 2008-2012. Morbidity and Mortality Weekly Report (MMWR), 63(23):511-515.
10. Melenotte C, Zandotti C, Gautret P, et al (2018). Measles: is a new vaccine approach needed? Lancet Infect Dis, 18(10):1060-1061.
11. Papania M, Wharton, M and Redd Measles (2002). VPO surveillance Manual. 3rd ed.
12. Minal K. Patel, Laure Dumolard, et al (2018). Progress toward regional measles elimination—worldwide, 2000–2018. MMWR, 67(47):1323.
13. Khorrami SM, Mokhtari-Azad T, Yavarian J, et al (2015). The etiology of Rubella IgM positivity in patients with rubella-like illness in Iran from 2011 to 2013. J Med Virol, 87(11):1846-1852.
14. Bankamp B, Byrd-Leotis LA, Lopareva EN, et al (2013). Improving molecular tools for global surveillance of MeV. J Clin Virol, 58(1):176-182.
15. Nasab F, Sadat G, Salimi V, et al (2016). Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1, and B3) in Iran. Pathog Dis, 74(8) ftw089.
16. Zahraei SM, Gouya MM, Mokhtari Azad T, et al (2011). Successful control and impending elimination of measles in the Islamic Republic of Iran. J Infect Dis, 1:S305-11.
17. Mondiale de la Santé O, Organization WH (2018). Creating new solutions to tackle old problems: the first ever evidence-based guidance on emergency risk communication policy and practice. Wkly epidemiol rec, 93(6):45-54.
18. Shi J, Zheng J, Huang H, et al (2011). Measles incidence rate and a phylogenetic study of contemporary genotype H1 measles strains in China: is an improved measles vaccine needed? Virus genes, 43(3):319-326.
19. Tahara M, Takeda M, Seki F, et al (2007). Multiple amino acid substitutions in H are necessary for wild-type MeV to acquire the ability to use receptor CD46 efficiently. J virol, 81(6):2564-72.
20. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R (2004). Selectively receptor-blind MeVes: identification of residues necessary for SLAM-or CD46-induced fusion and their localization on a new H structural model. J virol, 78(1):302-313.
21. Yanagi Y, Takeda M, Ohno S, Hashiguchi T (2009). Measles virus receptors. Curr Top Microbiol. Immunol, 329:13-30.
22. Hashiguchi T, Ose T, Kubota M, et al (2011). Structure of the MeV H bound to its cellular receptor SLAM. Nat Struct Mol, 18(252):135-41.
23. Mogling R, Richard MJ, Vliet SV, et al (2017). Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site. J Gen Virol, 98(6):1274-1281.
24. Perabo L, Goldnau D, White K, et al (2006). Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J virol, 80(14):7265-7269.
25. Miyoshi M, Komagome R, Yamaguchi H, et al (2018). Genetic characterization of H protein of MeVes in Hokkaido district, Japan, 2006-2015. Microbiol Immunol, 62(6): 411-417
26. Finsterbusch T, Wolbert A, Deitemeier I, et al (2009). MeVes of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J Gen Virol, 90(11):2739-45.
27. Masresha BG, Dixon MG, Kriss JL, et al (2017). Progress Toward Measles Elimination—African Region, 2013–2016. MMWR, 66(17):436-443.
28. WHO: Measles virus nomenclature update: 2012. Wkly Epidemiol Rec 2012, 87: 73-80.
29. Loo MK, Sabahi F, Soleimanjdahi H, et al (2003). Seroprevalence of neutralizing antibodies to MeV in a vaccinated population in Iran, 1998. Eur J Epidemiol, 18(11):1085-9.
30. El Mubarak HS, Yüksel S, van Amerongen G, et al (2007). Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type MeVes. J Gen Virol, 88(7):2028-34.
31. Munoz-Alia MA, Muller CP, Russell SJ (2018). H-specific neutralization of subacute sclerosing panencephalitis viruses. PLoS One, 13(2):e0192245.
Files
IssueVol 52 No 8 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i8.13412
Keywords
Molecular analysis Hemagglutinin protein Amino acid substitution Vaccine efficacy B3 genotype
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Zareh-Khoshchehreh R, Salimi V, Fatemi Nasab GS, Naseri M, Adjami Nezhad Fard F, Mokhtari Azad T. Genetic Characterization of the H Gene of MeV Strains (H1, B3, and D4) Recently Circulated in Iran for Improving the Molecular Measles Surveillance in the National Measles Lab. Iran J Public Health. 2023;52(8):1730-1738.